Steve Grzanich has the business news of the day with the Wintrust Business Minute.

North Chicago-based AbbVie is buying Aliada Therapeutics for $1.4 billion. It’ll give AbbVie access to Aliada’s Alzheimer’s disease candidate. AbbVie has been making moves to bolster its neuroscience focus. It bought neuroscience and cancer drug developers earlier this year. Aliada’s Alzheimer’s drug is in early-stage development and could be a major new therapy. It utilizes a protein in the blood that carries iron to transport an antibody that degrades and eliminates brain plaque connected to Alzheimer’s.

Also, a New York Attorney General investigation into Capital One’s proposed acquisition of Discover Financial Services could slow the deal. Listen for more below: